TrialCancer2019

A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.

Evanthia Galanis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.